MANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.

Similar documents
IF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?

The World Health Organization (WHO) has described diabetes mellitus as Metabolic

Index. Foot Ankle Clin N Am 11 (2006) Note: Page numbers of article titles are in boldface type.

If Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017

Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

pdpn early screening and management

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Diabetic Peripheral Neuropathy: Assessment and Treatment

Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks

Painful Diabetic Neuropathy Effective Management. Ketan Dhatariya Consultant in Diabetes NNUH

PDF of Trial CTRI Website URL -

Diabetic Retinopathy and Neuropathy: 2018 Clinical Practice Guidelines

Medications for the Treatment of Neuropathic Pain

Persistent Pain in Secure Environments Health and Justice Pharmacy Network Meeting Tuesday 18 March 2014

Kim Chong Hwa MD,PhD Sejong general hospital, Division of endocrine & metabolism

Spinal Cord Injury Pain. Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018

Diabetic Peripheral Neuropathic Pain: Evaluating Treatment Options

Practical upates in Diabetes & CV risk management: Brief Updates Neurological complications in diabetes

Elements for a Public Summary

Neuropathic Pain in Palliative Care

Prof dr Aleksandar Raskovic DIRECT VASODILATORS

Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD

LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS

Executive Summary Pregabalin (Lyrica by Pfizer) Formulary Review

Pain CONCERN. Medicines for long-term pain. Antidepressants

Disclosures. Objectives 9/8/2015

3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo

Roadmap: PIFP and PTTN

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

GABAPENTIN. THERAPEUTICS Brands Neurontin see index for additional brand names

Non-opioid and adjuvant pain management

Anti-Depressant Medications

Optimizing Non-Opioid Therapy for Chronic Pain

Understanding Fibromyalgia

HIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1

Diabetic Neuropathy. Nicholas J. Silvestri, M.D.

SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)

See Important Reminder at the end of this policy for important regulatory and legal information.

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE

Management of Pain related to Spinal Cord Lesion

CHAPTER 4 PAIN AND ITS MANAGEMENT

Neuropathic Pain and Pain Management Options. Mihnea Dumitrescu, MD

Neuropathic Pain Treatment Guidelines

REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

CONCORD INTERNAL MEDICINE. Peripheral Neuropathy. April 22, 2012

The Nervous System. Chapter 4. Neuron 3/9/ Components of the Nervous System

Managing Pain in the Elderly

Complications of Diabetes: Screening and Prevention

Invokana (canagliflozin) NEW INDICATION REVIEW

Managing Diabetic Peripheral Neuropathic Pain

1/21/14. Barriers to Assessment and Management of Chemotherapy- Induced Peripheral Neuropathy. Conflicts of Interest. Learning Objective

Acute Pain NETP: SEPTEMBER 2013 COHORT

Advice following an Independent Review Panel (IRP)

Fibromyalgia. Resident School December 2013 Mary Lemon

Diabetic Neuropathy An Overview. Dr. Mark Hannon MD MSc FRCPI Consultant Physician and Endocrinologist Bantry General Hospital Septebmer 20 th 2017

Palliative Prescribing - Pain

Complications of Diabetes: Screening and Prevention. Dr Martin McIntyre Consultant Physician Royal Alexandra Hospital Paisley

Inernal Medicine by Prof. El Sayed Abdel Fatah Eid. Diabetes Mellitus. Prof. El Sayed Abdel Fattah Eid. Lecturer of Internal Medicine Delta University

National Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007

Strategies in Migraine Care

Overview of Neuropathic pain

Diabetes Overview. How Food is Digested

Cell communication. Gated ion channels. Allow specific ions to pass only when gates are open

Cell communication. Gated ion channels. Voltage-Gated Na + Channel. Allow specific ions to pass only when gates are open

Omar Ismail. Dana Almanzalji. Faisal Mohammad

Approaches to Managing Neuropathic Pain. Nov 7, 2017

ADJUVANT PAIN MANAGEMENT

Modified version focused on CCNC Quality Measures and Feedback Processes

Treating Pain and Depression

Diabetes Review Chris Paras, D.O. Assistant Prof of Medicine, NYIT & Touro COM Designated Institutional Official & Assoc. Clinical Dean, Brookdale

Index. Clin Podiatr Med Surg 23 (2006) Note: Page numbers of article titles are in boldface type.

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Antidepressant Selection in Primary Care

THE NERVOUS SYSTEM. Homeostasis Strand

PAIN MEDICINE FOR THE NON-PAIN SPECIALIST 2017

Alpha-Lipoic Acid: A Versatile Antioxidant VRM

Multiple Mechanisms for Pain - How Can We Improve the Chances of Success?

Describe Identify Compare Recognize

Neuropathic Pain. Griffith Research Online. Author. Published. Journal Title. Copyright Statement. Downloaded from. Link to published version

A Review of Aldosterone Antagonists in Diastolic Heart Failure

This initial discovery led to the creation of two classes of first generation antidepressants:

5.9. Rehabilitation to Improve Central Pain

Pharmacological treatment of Pain

Neurons, Synapses, and Signaling

BEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN

The clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines

Diabetes Mellitus Aeromedical Considerations. Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Gateshead Pain Guidelines for Chronic Conditions

Understanding pain and mental illness Impact on management principles

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP

Microvascular Complications

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Standards of Medical Care In Diabetes

Disclosures. Management of Chronic, Non- Terminal Pain. Learning Objectives. Outline. Drug Schedules. Applicable State Laws

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Clinical Practice Guidelines for Diabetes Management

DysFUNctional Pain 5/19/2016. Potential conflicts of interest. Objectives

Transcription:

MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.

The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial symptom or sign

Contents Disease-modifying treatment Treatment of neuropathic pain To prevent complications of neuropathy

Disease-modifying treatment

Tight glucose control DCCT (5 yrs, type I with insulin), 1993 A relative risk reduction after 5yrs of 53% The beneficial effect on cardiac autonomic neuropathy

Clinical trials of enhanced control on neuropathy(type II)

Enhanced glucose control for preventing and treating diabetic neuropathy 17 randomized studies Types of outcome measures 1 outcome : annual development of clinical neuropathy 2 outcome : motor NCV, quantitative vibration Conclusions Type I : prevent the clinical neuropathy and reduce NCV/Vibration threshold (significantly) Type 2 : reduce the incidence of clinical neuropathy (not significantly)and reduce NCV/Vibration threshold Significantly increase the risk of severe hypoglycemia - Cochrane review 2012-

Tight glucose control The cornerstone of therapy Effectively slow the progression of diabetic neuropathy Delay the onset of neuropathy in Type I Significantly more effective in early diabetes

<Mechanisms of diabetic neuropathy>

Control of the Dyslipidemia High in type II diabetes Underlying mechanism FFA : inflammatory signals Modified LDL :oxidative stress Cholesterol : apoptosis Type II neuropathy Not typically develop rapidly, after many years of obesity linked to dyslipidemia A combination of Hyperglycemia, dyslipidemia and insulin resistance

Treatment of hypertension Thiazide diuretics Decreased sensitivity to glucose of pancreatic beta cell Aggravate abnormal glucose metabolism ACE inhibitor or ARB Some protective effect against microvascular complication and organ damage from diabetes Reduce the risk of diabetes or severity of diabetic neuropathy

Alpha lipoic acid (ALA) An orally bioavailable antioxidant (Thiotic acid ) SYDNEY 2 study, 2006 : randomized, double-blind, placebo-controlled : 600mg, 1200mg, 1800mg for 5 weeks : outcomes TSS, NIS, NSC : ALA groups improved neuropathic symptoms and deficits Intravenous infusion of 600mg of ALA for 3wks Effects : to influence the pathophysiology of neuropathy : to improve the endothelial dysfunction and blood flow : Caution - hypoglycemic pt, thiamine deficiency

Acetyl-L-carnitine Another antioxidant Inhibit lipid peroxidation and increase nitiric oxide synthase and nitiric oxide in experimental models Randomized, blinded control study : improved sural morphology and VAS Nutritional supplement, 500 mg daily Benfotiamine Vitamin B1 derivative, antioxidant Increasing vascular or microvascular blood flow Decompressive surgery

Pre-diabetes and neuropathy NCV tests at the time of diabetes diagnosis 10-18% : neuropathy Subclinical neuropathy The nerve injury occurs at the earliest stages of diabetes IGT or IFG One-third of adult Americans The effects of pre-diabetes on neuropathy uncertainty The diabetes Prevention Program (DPP) study Intensive diet and exercise / metformin treatment in IGT Metformin : less effective

Treatment of neuropathic pain

<Diabetic Neuropathic pain> - 40-60% of neuropathy - Distal symmetric, small fibers (C- and A fiber) - a negative impact of QOL

<A: established, B: probably, C: possibly, *ineffective or discrepant, + : not recommende>

Anticonvulsant (I) Pregabalin Level A evidence both EFNS and AAN Binds to the 2 - subunit of voltage-gated calcium channels -> reduces calcium influx at presynaptic terminals -> inhibit the release of excitatory neurotransmitters Anticonvulsant, anxiolytic activity, fibromyalgia 150mg -> 300-600 mg a day (Linear pharmacokinetics) half-life : 12hr

Anticonvulsant (II) Gabapentin Pain-modulating neurotransmitter Alteration of the synthesis and release of GABA Alteration of monoamine neurotransmitter release and blood serotonin levels Renal excretion 900mg ->2400-3600 mg a day Sodium valproate (trigeminal neuralgia and migraine), Oxcarbazepine, Lamotrigine : not recommended

Antidepressants (I) TCA (amitriptyline) A first-line treatment Mechanism Inhibition of norepinephrine serotonin reuptake within CNS Alpha-adrenergic blockade, sodium channel block, NMDAreceptor antagonism Inexpensive, sleep initiation, hypotension, 25-100 mg (beginning at 10mg) Caution Partial or complete heart block (esp old pts), MI Nortriptylin reduced side effect

Antidepressants (II) SNRI Duloxetine (Cymbalta ) Balanced selective serotonin /norepinephrine reuptake inhibitor 60-120 mg FDA-indicated Depression, anxiety, fibromyalgia Not recommended in ESRD, hepatic impairment Venlafaxine More effective in high dose(150-225mg) Combination with gabapentin : improvement in mood and QOL

Opioids Oxycodone Adjunct treatment in poorly controlled neuropathic pain Combination of gabapentin More pain relief Constipation, dry mouth Tramadol Binds to opiate receptors and block reuptake of serotonin and norepinephrine A low potential for abuse 50-100mg -> 200-400 mg a day

<Algorithm for the treatment of diabetic painful neuropathy>

To prevent complications of neuropathy

Complication of diabetic neuropathy The primary cause of the majority of diabetic foot Foot ulceration and amputation Increase the risk of ulcer sevenfold Over 60% of L/E amputation Related to duration of neuropathy and severity of hyperglycemia Diabetic charcot s neuroarthropathy Falls At higher risk of falling (Diabetic pt over 55 yrs : 1/3) Sensory loss, distal weakness, diabetic retinopathy

Prevention of Diabetic foot Patient s education Daily self examination Good shoes for diabetic foot Visit to diabetic specialist (foot care) Toenail Corn and callus

<corn and callus>

Shoe Length / width Toe box Confirm heel counter Soft upper part Seamless inner surface Rocker bottom To confirm the foreign body in shoe

Take home message Diabetic neuropathy Tight glucose control Treatment of neuropathic pain Neuropathic pain 1 st line : pregabalin, TCA, SSRI 2 nd line : tramadol, opioid Prevention of the diabetic foot Good shoes Regular exam and foot care

Thank you for your attention!!